Combretastatin A4

For research use only.

Catalog No.S7783

3 publications

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Selleck's Combretastatin A4 has been cited by 3 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;FPY1EgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO Ml\KNVg4PTN3MB?=
A-549 MmTWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fjXGN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGEuPTR7IHz1coch[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:OS5{MFWtNFYh|ryP MX2xPFc2OzVy
MCF-7 NH;Md3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDNR2YuPyCkcnXhd5Qh[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:Oy56MFWtNFYh|ryP MWCxPFc2OzVy
HT-29 NF\tNXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\oTFJxS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hUFRvMkmgZ49td25iYXTlco9k[XKlaX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjJyRT2wOkDPxE1? MYexPFc2OzVy
MLM melanoma cell M33TSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWPVVIxoS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hVUyPIH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;MT60NGUuODZizszN NGPmTGsyQDd3M{Ww
M14 Mon4R5l1d3SxeHnjbZR6KGG|c3H5 NXrtUVBYUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczD0[ZN1\WRiYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk[W6lZYKgLG0yPCliY3XscEBtcW6nLDDHTVUxRTBwMECwNUDPxE1? M2rOXFEzPzJ7NkSw
SK-OV3 NFnud45EgXSxdH;4bYNqfHliYYPzZZk> MXnJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImgeIV{fGWmIHHnZYlve3RiaIXtZY4hd3[jcnnhckBk[W6lZYKgLHNMNU:YMzmgZ4VtdCCuaX7lMEBIUTVyPUCuNFAxOSEQvF2= MmDmNVI4Ojl4NEC=
HL60 cells NX34NoI3S3m2b4TvfIlkcXS7IHHzd4F6 NWLB[FVnPzJiaB?= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFAyKM7:TR?= MVSyNFc{OTN3NR?=
SK-OV-3 MmPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWT4cHB3PDhiaB?= M{Dqemdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNFE{KM7:TR?= NVvlbm5ROTh5MkKxNlc>
HepG2 cells NHjCWlREgXSxdH;4bYNqfHliYYPzZZk> MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whUUN3ME2wMlAxODF2IN88US=> NI\xcnAyPzF{N{C2NS=>
ZR-75-1 MnSwR5l1d3SxeHnjbZR6KGG|c3H5 MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> NGHa[2wyPzJ2OU[0PS=>
HeLa cell NXPydXY1S3m2b4TvfIlkcXS7IHHzd4F6 MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBJ\UyjIHPlcIwhdGmwZTygTWM2OD1yLkCwNFMh|ryP MkW2NVczPDl4NEm=
HCT116 cell NHnod2REgXSxdH;4bYNqfHliYYPzZZk> NH2yVFJEgXSxdH;4bYNqfHliYXfhbY5{fCCKQ2SxNVYh[2WubDDsbY5mNCCLQ{WwQVAvODByM{Wg{txO NYfoWIFOOTd{NEm2OFk>
KBV1 cells MVHDfZRwfG:6aXPpeJkh[XO|YYm= MX[3NkBp NFXKN5NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB3cW6kbHHzeIlv\S2{ZYPpd5RidnRiS1LWNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOEDPxE1? NV;V[2NoOjB5M{GzOVU>
SKOV3 MmTHR5l1d3SxeHnjbZR6KGG|c3H5 NH;oNJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= MXSyOFAyPjByMh?=
SKOV3 cells NHWweWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnvPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODR{IN88US=> M4jVUVI{Pzd{M{C5
HeLa cells NHLYW|ZEgXSxdH;4bYNqfHliYYPzZZk> NG\ZTYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUyKM7:TR?= MlfhNVk5Pzl5NUi=
DU145 cells NX3UZmk4S3m2b4TvfIlkcXS7IHHzd4F6 MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1OEDPxE1? NYnjUoN{OjRyMU[wNFI>
DU145 cells MluwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWDHZZBKT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMEW0JO69VQ>? MoPZNlM4PzJ|MEm=
SK-N-BE MkLLVJJwdGmoZYLheIlwdiCjc4PhfS=> NFzRT4Q4OiCq MkL3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gV2suVi2ERTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNUig{txO MkPNNlI{Ojl3NkG=
NCIH460 cells NWnEXWNMS3m2b4TvfIlkcXS7IHHzd4F6 M3u2OVQ5KGh? MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2lJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB4IN88US=> MmfsNVg{ODN6NEm=
KB-VIN10 cells MYrQdo9tcW[ncnH0bY9vKGG|c3H5 MnjKO|IhcA>? MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO NHzDbIszOTZ2MUewNC=>
HCT116 cells MoXvR5l1d3SxeHnjbZR6KGG|c3H5 NG\BcII4OiCq MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? MX[yNVk2PTR3NB?=
DU145 cells NULqWWhDS3m2b4TvfIlkcXS7IHHzd4F6 NHLjflc1QCCq M2rrcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODB6IN88US=> NGrkZWEyQDNyM{i0PS=>
RS4:11 cells NXLifo9lWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUS3NkBp NFP1T2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLTOFoyOSClZXzsd{Bi\nSncjC3NkBpenNiYomgLFMuMDRuNT3kbY1mfGi7bITobYF7d2xvMj35cEkuOix3LXTpdIhmdnmudHX0doF7d2yrdX2gZpJwdWmmZTD0[ZN1NCCLQ{WwQVAvODByODFOwG0> Mk\jNlU4QDV4MEW=
HCT 116 NGHycFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= M3fkXlEyPzF2NkGz
HeLa cells NWHrZldTS3m2b4TvfIlkcXS7IHHzd4F6 Mnz2O|IhcA>? NXPHOIN2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA4OiCqcoOgZpkhemW|YYr1dolvKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlAxODlizszN NHXESoUzPDZ4OUi4PC=>
BNL 1ME A.7R.1 cells NYntcmhqS3m2b4TvfIlkcXS7IHHzd4F6 M2e5cWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJPVCBzTVWgRU44Wi5zIHPlcIx{NCCLQ{WwQVAvODByOTFOwG0> MVWyOVc5PTZyNR?=
Calu6 NYrrSpZKWHKxbHnm[ZJifGmxbjDhd5NigQ>? MknpOFghcA>? MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIW2JIFnfGW{IES4JIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eTygTWM2OD1yLkCwNFk1KM7:TR?= MUiyNVc4PDR7OR?=
melanoma B16 cell NFvDTW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVP0SFV7S2:wY3XueJJifGmxbjD3bIlkcCCycn;keYNmeyB3MDWgbY5pcWKrdHnvckBw\iCpcn;3eIghd2ZibYXybY5mKG2nbHHuc41iKEJzNjDj[YxtKGyrbnWsJGlEPTB;MD6wNFEh|ryP MnfWNVE4OTR4MUO=
DU145 cells M3jNNmN6fG:2b4jpZ4l1gSCjc4PhfS=> MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO NVvwb4VUOjB2OU[5NlM>
HCT116 cells M4HpNXBzd2yrZnXyZZRqd25iYYPzZZk> M1f6SVczKGh? M371ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MmjxNlEyOTJzM{C=
HCT15 cells MofwVJJwdGmoZYLheIlwdiCjc4PhfS=> NVLsOnUzPzJiaB?= M{XabWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? NH\mS5IzOTFzMkGzNC=>
HL60 cells MlflVJJwdGmoZYLheIlwdiCjc4PhfS=> M13RNVczKGh? MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MnXVNlE3PjN|MUm=
A10 cells NV7BN|E1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfDZVdxPDhiaB?= M3jicGdzd3e2aDDpcohq[mm2aX;uJI9nKHKjdDDBNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NEfkOnozOjB2NEG2OC=>
HUVEC cells NE\CPGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUm0PEBp NHXEXo5Iem:5dHigbY5pcWKrdHnvckBw\iCKVW\FR{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NICz[pczOjB2NEG2OC=>
HL60 cells NX;EfI0zS3m2b4TvfIlkcXS7IHHzd4F6 NFnoZWM4OiCq NX7Ub3k6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NWjUfGRWOjJzM{[zNVI>
HL60 cells NF7YW3RRem:uaX\ldoF1cW:wIHHzd4F6 M3;xc|czKGh? MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NXfaT5hmOjJ3N{ixNVE>
NCI-H522 cells M4XLUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWq0PEBp MnnxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh3MkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> Ml;yNlI6QDJzMkK=
MDA-MB-435 cells NG\jVnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnryOFghcA>? M3HnWWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MnvpNlI6QDJzMkK=
OVCAR3 MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfCbGo1QCCq M1zaTGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> M2fGZVIzQTh{MUKy
NCI/ADR-RES cells MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\iN4djPDhiaB?= MYLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? M1vZW|IzQTh{MUKy
PC3 cells NUOyT2FtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUPXfHVGPDhiaB?= M{DaOWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= MViyNlk5OjF{Mh?=
DU145 cells M37wN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYG0PEBp MkLsS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= M{GwOVIzQTh{MUKy
MDA-MB-231 cells MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1fEZ|Q5KGh? NY\1UmRzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NHPtOXozOjl6MkGyNi=>
CEM cells MmH2R5l1d3SxeHnjbZR6KGG|c3H5 NWfRS|RNPzJiaB?= M3fhe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MV:yNlY4PjJ2Nx?=
HCT116 cells NF74VnFEgXSxdH;4bYNqfHliYYPzZZk> NUn2O3A4PzJiaB?= NXnWU5loS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NX7XeZFIOjJ4N{[yOFc>
MDA-MB-435 cells NVjVWWFkS3m2b4TvfIlkcXS7IHHzd4F6 NGrsUGs4OiCq NFLhV5BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NHzmVlAzOjZ5NkK0Oy=>
HaCaT cells Mk\YVJJwdGmoZYLheIlwdiCjc4PhfS=> NXLm[HpiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIZWNiXCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MV2yN|A3OzRyMR?=
HL60 cells Mlj2VJJwdGmoZYLheIlwdiCjc4PhfS=> MlnDO|IhcA>? MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> NIjvco8zOzFzN{G3NS=>
HL60 cells NVLNW|lLWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkTzO|IhcA>? MlLvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSBqMz2oOEw2NWSrbXX0bJltfGirYYrvcE0zNXmuKT2yMFUu\GmyaHXufYx1\XS{YYrvcIl2dSCkcn;tbYRmKHSnc4SsJGlEPTB;MD6wNFEh|ryP NUDXdGplOjV5OEW2NFU>
HT-29 MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\mS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MoXjNlU3QDlzMUG=
HL60 cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NWPXXJBtPzJiaB?= M1\mWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NHXLeZEzODR{MESzPS=>
Hs578T cells MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXIclk1QCCq MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MkHuNlI6QDJzMkK=
HL60 cells NFjrWIhEgXSxdH;4bYNqfHliYYPzZZk> MUK3NkBp M4XaR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MUOyN|Q1PTR7Nh?=
SKOV3 cells MmLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NVjsV|VzOjV4OEmxNVE>
MDA-MB-468 cells M3K4UGN6fG:2b4jpZ4l1gSCjc4PhfS=> MnnXOEBl[Xm| NWTHcplHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0JIRigXNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyOSEQvF2= NIXTOoEzPDJzMEWwNy=>
MCF7 cells NHj3b2JRem:uaX\ldoF1cW:wIHHzd4F6 MknTO|IhcA>? NXn1[ppZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzMUGg{txO M2e0TVIzOzJ7NU[x
H460 NYDiZ3prS3m2b4TvfIlkcXS7IHHzd4F6 M3PTeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiC2ZYP0MEBKSzVyPUCuNFAyOiEQvF2= NH65VFAyQDd6M{KwOy=>
H460 MVzQdo9tcW[ncnH0bY9vKGG|c3H5 NHraUJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOsJGlEPTB;MD6wNFEzPCEQvF2= MYGxOlczOjZ|Mx?=
NCI-H460 cells NWXBVmJwS3m2b4TvfIlkcXS7IHHzd4F6 NXezWWxTPzJiaB?= MUjDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjD0[ZN1NCCLQ{WwQVAvODBzMzFOwG0> NELaSWgyQDN7Nki1Oy=>
OVCAR8 cells NGXQVZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmW4PVYhcA>? NUfXSIR1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK4JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ3z5Z49xem:2ZXnuJIFnfGW{IEm2JIhzeyxiSVO1NF0xNjByMUOg{txO M1vMSVIzODR2MU[0
NCI/ADR-RES cells MlnlR5l1d3SxeHnjbZR6KGG|c3H5 NIPFOZVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= NYTRT20{OjN{MUS0OVI>
OVCAR8 cells MXLDfZRwfG:6aXPpeJkh[XO|YYm= NVHxbo5{QTZiaB?= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? M{[0UFI2ODJ3OUmx
NCI/ADR-RES cells MnXUR5l1d3SxeHnjbZR6KGG|c3H5 Ml;wPVYhcA>? MnnHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgPVYhcHK|IHL5JGdq\W2|YTDzeIFqdmmwZz3iZZNm\CCuaXfoeEBucWO{b4Pjc5B6NCCLQ{WwQVAvODBzMzFOwG0> MVWyOVAzPTl7MR?=
OVCAR8 cells MknKR5l1d3SxeHnjbZR6KGG|c3H5 NWP0e3BHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigSxiSVO1NF0xNjByMUOg{txO M1jxeVI{OjF2NEWy
HuTu 80 cells MkW5VJJwdGmoZYLheIlwdiCjc4PhfS=> NETaeI44OiCq MmrjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gTJVVfSB6MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzM{eg{txO MVOyNlMzQTV4MR?=
K562 cells M1zybmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUCuNFAyPCEQvF2= M1u0dVE6QDN5NUm0
NCI/ADR (MDR) cells M{PDTWZ2dmO2aX;uJIF{e2G7 NUHnSlhJS2WubDDjfYNt\SCjcoLld5QhcW5iTlPJM2FFWiBqTVTSLUBk\WyuczDifUBi[2O3bYXsZZRqd25iYYSgS|IwVSCyaHHz[UwhUUN3ME2wMlAxOTVizszN NXu3V5hLOTZ|N{exPFc>
HUVEC Mn3lVJJwdGmoZYLheIlwdiCjc4PhfS=> MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiXVlXDMEBKSzVyPUCuNFAyPSEQvF2= M{HhWlE3PzJ{NkOz
KB cell NIT5NI1Rem:uaX\ldoF1cW:wIHHzd4F6 NED2bopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCJINmdGxibHnu[UBjgSCvZYTofYxmdmViYnz1[UBlgWViYYPzZZktKEmFNUC9NE4xODF3IN88US=> M32wbFE4ODN2MUS3
KB-VIN10 cell MVrQdo9tcW[ncnH0bY9vKGG|c3H5 NWLkUWlXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= NGLUcnUyPzB|NEG0Oy=>
Human SH-SY5Y neuroblastoma cells M3PqPGZ2dmO2aX;uJIF{e2G7 NXvVVVhCUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? MUOxOVk3Ozd{Mh?=
SW620 cells MVjQdo9tcW[ncnH0bY9vKGG|c3H5 M{\1fFczKGh? M3vWO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNYPjJyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF3MjFOwG0> MmewNlI{Ojl3NkG=
Molt4/C8 cells MWnQdo9tcW[ncnH0bY9vKGG|c3H5 M3i3SWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> MkfMNVcxOzRzNUC=
ACHN cell M3\JW3Bzd2yrZnXyZZRqd25iYYPzZZk> NFzWXpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIRzfWdicnXzbZN1[W62IFHDTG4h[2WubDDsbY5mKGW6cILld5NqdmdiTVTSNUBjgSCDbHHtZZIhSmy3ZTDhd5NigSxiSVO1NF0xNjByMU[g{txO M3;LTVE4Ojh4M{mz
Molt4/C8 cells MULQdo9tcW[ncnH0bY9vKGG|c3H5 MnrUN{Bl[Xm| MnrHRY51cXC{b3zp[oVz[XSrdnWg[YZn\WO2IHHnZYlve3RiaIXtZY4hVW:udESvR|gh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvODBzNjFOwG0> M2H3c|E4PDF7NkC3

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID